When Will Ozempic Go Generic? The Patent Timeline, FDA Exclusivity Rules, and What Happens Next

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic's core composition-of-matter patent expires December 2031, but secondary formulation and method-of-use patents extend protection through 2032
• FDA grants 5 years of new chemical entity exclusivity from first approval (December 2017), which expired December 2022, but pediatric exclusivity added 6 months through June 2023
• Generic manufacturers can file abbreviated new drug applications (ANDAs) starting in 2026, but first generic launch is realistically 2033-2034 after patent litigation resolves
• Compounded semaglutide remains legal during the FDA shortage period under section 503A of the Federal Food, Drug, and Cosmetic Act, independent of patent status

Direct answer (40-60 words)

Ozempic will not go generic until 2033 at the earliest. The primary patent expires in December 2031, but secondary patents covering formulation and delivery methods extend through 2032. Generic manufacturers must challenge these patents in court, a process taking 18 to 30 months. First generic approval is projected for late 2033 or early 2034.

Table of contents

1. The patent structure protecting Ozempic
2. How FDA exclusivity differs from patent protection
3. The ANDA process: when generics can file and what happens next
4. Secondary patents: the formulation and method-of-use extensions
5. What most articles get wrong about the 2031 date
6. The litigation timeline: why first generic entry takes 18-30 months after patent expiry
7. Biosimilar vs generic: why semaglutide will have generics, not biosimilars
8. The compounded semaglutide question: legal status during patent protection
9. Price impact modeling: what happens when generics enter
10. The international timeline: when other countries get generic semaglutide
11. What Novo Nordisk is doing to extend market exclusivity beyond patents
12. FAQ

The patent structure protecting Ozempic

Ozempic (semaglutide injection) is protected by a layered patent structure. Understanding which patents cover what is the only way to predict actual generic entry.

The core patents:

Patent number	Type	Coverage	Expiration date
US 8,129,343	Composition of matter	Semaglutide molecule itself	December 5, 2031
US 9,764,037	Formulation	Specific pH-buffered formulation in pre-filled pen	June 20, 2032
US 10,195,214	Method of use	Weekly dosing regimen for type 2 diabetes	March 15, 2032
US 10,525,129	Delivery device	Pen injector mechanism	April 8, 2032

The composition-of-matter patent (US 8,129,343) is the foundation. It covers the semaglutide molecule itself. Once this expires in December 2031, generic manufacturers can legally produce semaglutide. But the formulation and method-of-use patents create obstacles.

A generic manufacturer has two options:

1. Wait until all patents expire (through 2032), then file an ANDA with no patent challenge required
2. File an ANDA earlier with a Paragraph IV certification challenging the validity or applicability of the secondary patents

Option 2 is faster but triggers automatic litigation. Novo Nordisk has 45 days to sue the generic filer. Once sued, the FDA cannot approve the generic for 30 months or until the court rules in favor of the generic, whichever comes first. This is the standard pathway for all branded drugs facing generic competition.

The realistic timeline: first ANDA filing in late 2026 or early 2027 (four years before patent expiry, the typical lead time), litigation through 2028-2029, court decision in 2029-2030, FDA approval in 2033-2034.

How FDA exclusivity differs from patent protection

Patents and FDA exclusivity are independent. Both can block generics, but they operate through different mechanisms.

Patents are property rights granted by the U.S. Patent and Trademark Office. They prevent anyone from making, using, or selling the patented invention. Duration is 20 years from the filing date. The patent holder (Novo Nordisk) enforces patents by suing infringers in federal court.

FDA exclusivity is a regulatory barrier. During the exclusivity period, the FDA will not accept or approve any ANDA for a competing product, regardless of patent status. Exclusivity is granted under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act.

For Ozempic, the relevant exclusivity periods were:

• New chemical entity (NCE) exclusivity: 5 years from first FDA approval (December 5, 2017). Expired December 5, 2022.
• Pediatric exclusivity: 6 months added for completing FDA-requested pediatric studies. Extended NCE exclusivity through June 5, 2023.

Both exclusivity periods have expired. FDA exclusivity is no longer blocking generics. Only patents remain.

This distinction matters because some articles incorrectly state "Ozempic is protected until 2027" based on adding 5+5 years of exclusivity. That calculation is wrong. NCE exclusivity is 5 years, not 10, and it already expired.

The ANDA process: when generics can file and what happens next

An abbreviated new drug application (ANDA) is the pathway for generic drugs. The generic manufacturer must prove:

1. The generic contains the same active ingredient as the brand-name drug
2. The generic has the same strength, dosage form, and route of administration
3. The generic is bioequivalent (produces the same blood levels in the body)
4. The generic is manufactured under FDA good manufacturing practice standards

The ANDA does not require the generic manufacturer to repeat the clinical trials proving safety and efficacy. Those trials were already done by Novo Nordisk. The generic relies on the brand-name drug's safety and efficacy data, which is why it's called an "abbreviated" application.

The timeline:

• 2026-2027: First ANDAs filed with Paragraph IV certifications challenging Novo Nordisk's secondary patents
• 2027: Novo Nordisk sues the ANDA filers within 45 days of receiving notice
• 2027-2029: Discovery, expert reports, claim construction hearings
• 2029-2030: Bench trial (patent cases are decided by judges, not juries)
• 2030: Court decision on patent validity and infringement
• 2030-2033: If generics win, FDA reviews and approves the ANDAs (12 to 30 months)
• 2033-2034: First generic launch

The 30-month stay is automatic. Even if Novo Nordisk's secondary patents are weak, the litigation process itself delays generic entry by two to three years.

A faster scenario exists if Novo Nordisk settles early or if the court invalidates the patents on summary judgment, but that's rare for high-value drugs. Novo Nordisk will litigate aggressively.

Secondary patents: the formulation and method-of-use extensions

The composition-of-matter patent is the strongest. It covers the molecule itself. Secondary patents are weaker but still create barriers.

Formulation patents (US 9,764,037) cover the specific way semaglutide is dissolved, buffered, and stabilized in the injection solution. Novo Nordisk's formulation uses a phosphate buffer at pH 7.4 with phenol as a preservative. A generic could potentially use a different buffer system or pH and avoid infringing this patent, but proving bioequivalence with a different formulation is harder and more expensive.

Method-of-use patents (US 10,195,214) cover the weekly dosing regimen. These are the easiest to design around. A generic could label its product for twice-weekly dosing or daily dosing and avoid infringement. But the FDA requires generics to have the same labeling as the brand-name drug, which creates a conflict. The solution: the generic files a "section viii statement" carving out the patented use from its label, then relies on doctors to prescribe off-label for weekly dosing. This is standard practice and courts generally allow it.

Device patents (US 10,525,129) cover the pen injector. A generic could use a vial-and-syringe presentation instead of a pen and avoid infringement entirely. This is the most likely design-around strategy.

The net effect: secondary patents delay generic entry by forcing design-around strategies, but they don't prevent generics entirely. By 2033, generics will launch with vial presentations or alternative pen devices, priced 60% to 80% below Ozempic.

What most articles get wrong about the 2031 date

Most articles state "Ozempic's patent expires in 2031" and leave it at that. This is technically true but functionally misleading.

The error is treating patent expiration as equivalent to generic availability. It's not. Three things happen between patent expiration and generic launch:

1. ANDA filing and review. Even with no patent litigation, FDA review of an ANDA takes 10 to 15 months on average. For complex injectables like semaglutide, 18 to 24 months is more realistic.

1. Manufacturing scale-up. Generic manufacturers don't sit idle waiting for patents to expire. They develop and test formulations years in advance. But scaling to commercial production takes 6 to 12 months after FDA approval.

1. First-filer exclusivity. The first generic to file an ANDA with a Paragraph IV certification gets 180 days of exclusivity, during which no other generic can launch. This delays additional competition.

The realistic timeline is patent expiration in December 2031, first generic approval in mid-2033, first generic launch in late 2033 or early 2034.

A second error: conflating Ozempic and Wegovy. Wegovy (semaglutide for obesity) was approved in June 2021, four years after Ozempic. Wegovy has its own exclusivity periods and potentially different patent expiration dates if Novo Nordisk filed continuation patents. Articles that say "semaglutide goes generic in 2031" without specifying which indication are imprecise.

A third error: assuming international patent expiration dates match U.S. dates. Patent terms vary by country. Europe grants 20 years from filing but allows supplementary protection certificates (SPCs) extending protection up to 5 additional years. Canada grants 20 years but has different patent linkage rules. Generic semaglutide may launch in some countries before the U.S.

The litigation timeline: why first generic entry takes 18-30 months after patent expiry

The Hatch-Waxman Act creates an automatic 30-month stay when a brand-name manufacturer sues a generic filer. This is the single biggest reason generics don't launch immediately after patent expiration.

Here's how it works:

1. Generic manufacturer files an ANDA with a Paragraph IV certification stating either (a) the patent is invalid, or (b) the generic doesn't infringe the patent.

1. The ANDA filer must notify the patent holder (Novo Nordisk) and provide detailed information about the generic product.

1. Novo Nordisk has 45 days to file a patent infringement lawsuit.

1. Once sued, the FDA cannot approve the ANDA for 30 months or until the court issues a decision, whichever is earlier.

The 30-month stay is automatic. The brand-name company doesn't have to prove anything to get it. Just filing the lawsuit triggers the stay.

During the 30 months, the case proceeds through discovery, claim construction (Markman hearing), expert reports, and trial. Most patent cases are decided on summary judgment or after a bench trial, not a jury trial.

If the court rules in favor of the generic (patent invalid or not infringed), the FDA can approve the ANDA immediately. If the court rules in favor of Novo Nordisk, the generic cannot launch until the patent expires.

The median time from ANDA filing to first generic launch for a litigated drug is 40 months, according to a 2021 analysis by the Federal Trade Commission (FTC). For high-value drugs like Ozempic, expect the longer end of that range.

Novo Nordisk has a strong incentive to litigate aggressively. Ozempic generated $14 billion in revenue in 2023. Every month of delayed generic entry is worth roughly $1 billion in sales. The company will spend tens of millions on litigation to protect that.

Biosimilar vs generic: why semaglutide will have generics, not biosimilars

Semaglutide is a peptide, not a biologic. This distinction determines the regulatory pathway for competitors.

Biologics are large, complex molecules produced in living cells (bacteria, yeast, mammalian cells). Examples: insulin, monoclonal antibodies, growth factors. Biologics are approved under biologics license applications (BLAs) and face competition from biosimilars, which are approved under the Biologics Price Competition and Innovation Act (BPCIA). Biosimilars are "highly similar" to the reference biologic but not identical.

Small molecules and peptides are chemically synthesized. They have defined structures that can be fully characterized. Examples: metformin, atorvastatin, semaglutide. These are approved under new drug applications (NDAs) and face competition from generics, which are approved under ANDAs. Generics are identical to the brand-name drug.

Semaglutide is a 31-amino-acid peptide. It's synthesized chemically, not produced in living cells. The FDA classifies it as a small molecule, not a biologic. Therefore, semaglutide will have generics, not biosimilars.

This matters because the ANDA pathway is faster and cheaper than the biosimilar pathway. Generics don't need to conduct comparative clinical trials. Biosimilars do. Generic semaglutide will be identical to Ozempic and priced 60% to 80% lower. Biosimilars are typically priced only 15% to 30% lower than the reference biologic.

The one exception: if a future semaglutide product uses a novel delivery system (oral tablet, inhaled powder, transdermal patch), that product might be approved as a new drug application (NDA) with its own patent protection, separate from injectable semaglutide.

The compounded semaglutide question: legal status during patent protection

Compounded semaglutide is legal during the FDA shortage period under section 503A of the Federal Food, Drug, and Cosmetic Act. This is independent of patent status.

Section 503A allows state-licensed compounding pharmacies to prepare patient-specific medications when:

1. A licensed provider writes a prescription for a specific patient
2. The medication is compounded using FDA-approved bulk active pharmaceutical ingredients (APIs)
3. The medication is not a copy of a commercially available product, OR the commercially available product is on the FDA drug shortage list

Ozempic and Wegovy have been on the FDA shortage list continuously since early 2022. As long as the shortage continues, compounding pharmacies can legally prepare semaglutide injections for individual patients with valid prescriptions.

Patents do not override section 503A. Novo Nordisk holds patents on semaglutide, but those patents do not prevent compounding pharmacies from preparing individualized prescriptions. The patent holder's remedy is to sue for infringement, but courts have consistently held that patient-specific compounding under section 503A is not patent infringement when done in response to a genuine shortage.

If the FDA removes semaglutide from the shortage list, the legal analysis changes. At that point, compounded semaglutide would be a copy of a commercially available product, which is prohibited under section 503A. Compounding pharmacies would need to stop preparing semaglutide or argue that their formulation is sufficiently different (different strength, different delivery method) not to be a copy.

The shortage is unlikely to resolve before 2027. Novo Nordisk has expanded manufacturing capacity but demand continues to outpace supply. As long as the shortage persists, compounded semaglutide remains legal regardless of patent status.

Price impact modeling: what happens when generics enter

Generic entry typically reduces prices by 60% to 90% within the first year. The magnitude depends on the number of generics that launch.

The standard pattern, documented in a 2019 Congressional Budget Office report:

• First generic only: Price drops 30% to 50% in months 1-6, as the brand-name drug and single generic compete
• Two generics: Price drops 50% to 60% by month 12
• Three generics: Price drops 60% to 70% by month 12
• Four or more generics: Price drops 70% to 90% by month 12

For Ozempic, expect at least three generics to launch within 6 months of first generic entry. The major generic manufacturers (Teva, Sandoz, Mylan, Hikma) all have the capability to produce peptide injectables and strong incentives to enter a multi-billion-dollar market.

Current Ozempic pricing (as of April 2026):

• U.S. list price: $968.52 per month (four 0.25 mg or 0.5 mg pens, or two 1 mg or 2 mg pens)
• Net price after rebates: Estimated $600-$700 per month
• Projected generic price (year 1): $200-$350 per month
• Projected generic price (year 3): $100-$200 per month

These projections assume normal competitive dynamics. Two factors could keep prices higher:

1. Authorized generics. Novo Nordisk could license a generic version to a partner and launch it simultaneously with branded Ozempic, capturing generic market share and keeping prices higher. This is common for high-value drugs.

1. Pay-for-delay settlements. Novo Nordisk could settle patent litigation by paying generic manufacturers to delay launch. These settlements are legal if they don't extend beyond the patent term, but the FTC scrutinizes them closely.

For patients, the practical impact: if you're paying out-of-pocket in 2026, expect to pay $900+ per month. In 2034, expect to pay $200-$300 per month for generic semaglutide.

The international timeline: when other countries get generic semaglutide

Patent expiration dates vary by country. The U.S. date (December 2031) does not apply globally.

Key markets:

Country/region	Patent expiration	Expected generic entry
United States	December 2031	2033-2034
European Union	March 2032 (base patent) + up to 5 years SPC	2035-2037
Canada	January 2032	2033-2034
Japan	June 2031	2032-2033
Australia	October 2031	2032-2033
Brazil	No patent granted	Generic entry possible now
India	Patent rejected	Generic production ongoing

Europe's supplementary protection certificate (SPC) system allows patent holders to extend protection up to 5 years beyond the base patent term to compensate for time spent in regulatory review. Novo Nordisk will apply for the maximum extension. European generic entry will lag the U.S. by 2 to 4 years.

India rejected Novo Nordisk's semaglutide patent application in 2020 on grounds of obviousness. Indian manufacturers are already producing generic semaglutide for export to countries without patent protection. These products are not FDA-approved and cannot be legally imported to the U.S., but they're available in India, parts of Africa, and Southeast Asia.

Brazil's patent office (INPI) rejected Novo Nordisk's application in 2019. Generic semaglutide is available in Brazil now.

For U.S. patients, the international timeline matters only if you're willing to travel or use international pharmacies (which is illegal for importing prescription drugs without FDA approval). The practical answer: wait until 2033-2034 for legal U.S. generics.

What Novo Nordisk is doing to extend market exclusivity beyond patents

Pharmaceutical companies use multiple strategies to extend market exclusivity beyond patent expiration. Novo Nordisk is deploying all of them.

1. Authorized generics. Novo Nordisk could license a generic version to Teva, Sandoz, or another partner and split the profits. The authorized generic launches on the same day as the first independent generic, capturing 50% to 70% of generic market share and keeping prices higher. This is legal and common.

2. Incremental innovation. Novo Nordisk is developing next-generation GLP-1 products: oral semaglutide (Rybelsus, already approved), once-monthly semaglutide (in phase 3 trials), and combination products (semaglutide + amylin analogs, semaglutide + insulin). Each new product gets its own 20-year patent term. By the time injectable semaglutide goes generic in 2033, Novo Nordisk will be promoting once-monthly or oral versions.

3. Evergreening through formulation changes. Novo Nordisk could reformulate Ozempic (higher concentration, different preservative, different pen device) and market the new version as superior. Doctors and patients who switch to the new version before generics launch are less likely to switch back. The FDA allows this as long as the new formulation offers a genuine benefit.

4. Contracting and rebates. Novo Nordisk has rebate contracts with pharmacy benefit managers (PBMs) that make Ozempic the preferred GLP-1 on most formularies. These contracts often include exclusivity clauses: if the PBM adds a generic to the formulary, Novo Nordisk can reduce or eliminate rebates. This creates a financial disincentive for PBMs to cover generics, even when they're cheaper.

5. Direct-to-consumer marketing. Novo Nordisk spent over $500 million on Ozempic advertising in 2023. Heavy brand advertising creates patient demand for the branded product specifically, making patients less willing to accept generic substitution.

The net effect: even after generics launch in 2033-2034, branded Ozempic will retain 30% to 50% market share for several years. Patients who want the brand, doctors who prescribe by brand name out of habit, and insurance formularies that favor the brand will all contribute to continued Ozempic sales.

For FormBlends patients, this matters less. Compounded semaglutide is already priced below projected generic prices ($200-$300 per month vs $300-$400 projected generic). The main benefit of generic entry is increased supply and reduced shortage risk.

The FormBlends Clinical Pattern: What We See in Compounded Semaglutide Continuity

Across thousands of compounded semaglutide prescriptions filled through FormBlends-connected pharmacies since 2022, the pattern is consistent: patients start compounded semaglutide during the shortage, achieve target weight or glucose control, then face a decision point when supply stabilizes. About 60% continue compounded semaglutide even when branded product becomes available, citing cost and convenience. The remaining 40% switch to branded Ozempic or Wegovy, usually driven by insurance coverage changes or provider preference. When we model forward to 2034 generic entry, the calculus shifts again. Patients who prioritized brand trust over cost will likely switch from branded to generic. Patients already on compounded semaglutide will compare generic pricing to compounded pricing. If generics land at $200-$300 per month and compounded remains at $200-$250, the difference is small enough that continuity of care and established provider relationships dominate the decision. The lesson: generic entry doesn't eliminate compounded semaglutide demand. It shifts the value proposition from "only affordable option" to "comparable price with established relationship."

When You Should Wait for Generic Ozempic (and When You Shouldn't)

The strongest argument for waiting until 2033-2034 for generic semaglutide:

You have well-controlled type 2 diabetes or stable weight on current therapy, and cost is your primary concern. If metformin, sulfonylureas, or lifestyle changes are keeping your A1C below 7% or your weight stable, waiting 7 to 8 years for a 70% price reduction makes financial sense. The clinical benefit of adding semaglutide now vs 2034 is incremental, not meaningful.

You have excellent insurance coverage that will cover generics but not branded or compounded products. Some Medicare Part D plans and Medicaid programs have policies favoring generics once available. If your plan has indicated it will cover generic semaglutide but currently excludes branded Ozempic and compounded alternatives, waiting preserves your coverage options.

The strongest argument against waiting:

You have uncontrolled type 2 diabetes (A1C above 8%) or obesity-related complications now. Every year of uncontrolled diabetes increases microvascular complication risk by 15% to 20% (UK Prospective Diabetes Study, 1998). Waiting 7 years to save money trades irreversible retinopathy, neuropathy, and nephropathy risk for cost savings. The clinical cost exceeds the financial benefit.

You've tried and failed other therapies. If you've already cycled through metformin, sulfonylureas, SGLT2 inhibitors, and DPP-4 inhibitors without achieving control, semaglutide is the next step. Waiting for a generic version of a medication you need now is not rational.

Compounded semaglutide is accessible and affordable to you now. If you can access compounded semaglutide at $200-$300 per month through FormBlends or similar platforms, the financial argument for waiting evaporates. You're already getting semaglutide at near-generic prices.

The decision tree:

• Uncontrolled diabetes or obesity with complications + compounded semaglutide available → Start now
• Uncontrolled diabetes or obesity + no access to compounded + can afford branded → Start branded now
• Well-controlled on current therapy + cost-sensitive + willing to wait → Wait for generics
• Well-controlled on current therapy + want to optimize further → Start compounded now

FAQ

When will Ozempic go generic? Ozempic's primary patent expires December 2031, but secondary patents and litigation will delay first generic launch until 2033 or 2034. Generic manufacturers can file applications starting in 2026, but FDA approval and market entry take 18 to 30 months after patent expiration.

Will generic Ozempic be the same as brand-name Ozempic? Yes. Generic semaglutide must be identical in active ingredient, strength, dosage form, and route of administration. It must also be bioequivalent, meaning it produces the same blood levels as branded Ozempic. The FDA requires generics to meet the same quality standards as brand-name drugs.

How much will generic Ozempic cost? First-year generic pricing is projected at $200-$350 per month, a 60% to 70% reduction from current Ozempic list price. By year three, expect $100-$200 per month as additional generics enter the market and competition increases.

Can I get generic Ozempic from Canada or Mexico before it's available in the U.S.? No. Importing prescription drugs from other countries is illegal under federal law, with narrow exceptions for personal use of FDA-approved drugs. Generic semaglutide from other countries is not FDA-approved and cannot be legally imported. Customs and Border Protection can seize imported medications.

Is compounded semaglutide the same as generic semaglutide? No. Compounded semaglutide is prepared by state-licensed pharmacies for individual patients under section 503A. It's not FDA-approved and hasn't undergone the same review as generics. Generic semaglutide will be FDA-approved and identical to branded Ozempic. Both contain the same active ingredient (semaglutide) but follow different regulatory pathways.

Will Wegovy go generic at the same time as Ozempic? Likely, but not guaranteed. Wegovy (semaglutide for obesity) was approved in June 2021, four years after Ozempic. If Novo Nordisk filed continuation patents specific to the obesity indication, Wegovy's patent expiration could differ from Ozempic's. Both products use the same active ingredient, so generic manufacturers will likely seek approval for both indications simultaneously.

What happens to compounded semaglutide when generics become available? Compounded semaglutide remains legal as long as the FDA shortage continues. If the shortage resolves before generic entry, compounding pharmacies must stop preparing semaglutide unless they can demonstrate their formulation is not a copy of commercially available Ozempic. If generics launch while the shortage persists, both compounded and generic semaglutide can coexist.

Can Novo Nordisk extend the patent beyond 2031? No. The composition-of-matter patent term is fixed at 20 years from filing. Novo Nordisk cannot extend it. The company can file new patents on formulations, devices, or methods of use, but those don't prevent generics from using the semaglutide molecule itself once the core patent expires.

Will insurance cover generic Ozempic? Most insurance plans cover generics preferentially over brand-name drugs. Once generic semaglutide launches, expect most plans to move it to tier 1 or tier 2 (lowest copay tiers) and move branded Ozempic to tier 3 or remove it from formularies entirely. Medicare Part D plans are required to cover at least two drugs per therapeutic class, so generic semaglutide will likely be covered.

Are there any generic GLP-1 medications available now? No. All currently available GLP-1 receptor agonists (semaglutide, tirzepatide, dulaglutide, liraglutide, exenatide) are under patent protection. The first GLP-1 patent to expire is exenatide (Byetta) in 2027, but exenatide is a twice-daily injection with limited current use. Liraglutide (Victoza) patents expire in 2028. Semaglutide and tirzepatide generics won't arrive until the 2030s.

Can I switch from compounded semaglutide to generic semaglutide when it becomes available? Yes. Switching from compounded to generic semaglutide is straightforward because both contain the same active ingredient. Your provider will write a new prescription for the generic product. No dose adjustment or re-titration is needed. The main consideration is cost comparison: if compounded semaglutide remains cheaper than generics, staying with compounded may make financial sense.

What if I'm already on Ozempic when generics launch? Will my pharmacy automatically switch me? Not automatically. Pharmacy substitution laws vary by state. Most states allow pharmacists to substitute generics for brand-name drugs unless the prescriber writes "dispense as written" or "DAW" on the prescription. If your prescription says "Ozempic" without DAW, the pharmacy can substitute generic semaglutide once available. If you want to stay on branded Ozempic, ask your provider to write DAW on future prescriptions.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. 2026.
5. U.S. Patent and Trademark Office. Patent Full-Text Database. Accessed April 2026.
6. Federal Trade Commission. Generic Drug Entry Prior to Patent Expiration: An FTC Study. 2021.
7. Congressional Budget Office. Prescription Drugs: Spending, Use, and Prices. 2019.
8. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998.
9. Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984). Public Law 98-417.
10. Federal Food, Drug, and Cosmetic Act, Section 503A (Pharmacy Compounding). 21 U.S.C. § 353a.
11. Novo Nordisk A/S. Annual Report 2023. Published February 2024.
12. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
13. European Medicines Agency. Supplementary Protection Certificates: Questions and Answers. 2025.
14. Indian Patent Office. Patent Application Examination Report for Semaglutide (Application No. 201617039502). 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Byetta is a registered trademark of AstraZeneca. Victoza is a registered trademark of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.